株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

有毛細胞白血病(HCL) - 市場調査、疫学、市場予測

Hairy Cell Leukemia (HCL) - Market Insight, Epidemiology and Market Forecast - 2030

発行 DelveInsight Business Research LLP 商品コード 524415
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
有毛細胞白血病(HCL) - 市場調査、疫学、市場予測 Hairy Cell Leukemia (HCL) - Market Insight, Epidemiology and Market Forecast - 2030
出版日: 2020年01月01日 ページ情報: 英文 150 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における有毛細胞白血病(HCL)の2018年の有病数は2,378人と推計されています。米国が最大の患者数を抱え、EU5カ国ではドイツの有病数が最も高くなっています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の有毛細胞白血病(HCL)市場を調査し、市場を調査し、疾病の概要や現行の治療法、新薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、有病数/罹患数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 主な洞察

第2章 市場概要

  • 有毛細胞白血病(HCL)の市場シェア(実績値)
  • 有毛細胞白血病(HCL)の市場シェア(予測値)

第3章 疾病背景と概要

  • イントロダクション
  • 兆候と症状
  • 疫学
  • 発病機序
  • 有毛細胞白血病(HCL)の仕組み
  • 病因
  • 診断
    • 腫瘍学におけるNCCN臨床診療ガイドライン
    • 欧州臨床腫瘍学会(ESMO):臨床診療ガイドライン
    • HCL-C診断のためのコンセンサスガイドライン

第4章 疫学と患者人口

  • 主な調査結果

第5章 主要7カ国における有毛細胞白血病(HCL)の総罹患数

第6章 有毛細胞白血病(HCL)の国別の疫学

  • 米国
    • 仮定と理論的根拠
    • 有毛細胞白血病(HCL)の罹患数
    • 有毛細胞白血病(HCL)の罹患数:症状別
    • 有毛細胞白血病(HCL)の罹患数:性別
    • 有毛細胞白血病(HCL)の罹患数:年齢別
  • EU5カ国
    • ドイツ
      • 有毛細胞白血病(HCL)の罹患数
      • 有毛細胞白血病(HCL)の罹患数:症状別
      • 有毛細胞白血病(HCL)の罹患数:性別
      • 有毛細胞白血病(HCL)の罹患数:年齢別
    • フランス
      • 有毛細胞白血病(HCL)の罹患数
      • 有毛細胞白血病(HCL)の罹患数:症状別
      • 有毛細胞白血病(HCL)の罹患数:性別
      • 有毛細胞白血病(HCL)の罹患数:年齢別
    • イタリア
      • 有毛細胞白血病(HCL)の罹患数
      • 有毛細胞白血病(HCL)の罹患数:症状別
      • 有毛細胞白血病(HCL)の罹患数:性別
      • 有毛細胞白血病(HCL)の罹患数:年齢別
    • スペイン
      • 有毛細胞白血病(HCL)の罹患数
      • 有毛細胞白血病(HCL)の罹患数:症状別
      • 有毛細胞白血病(HCL)の罹患数:性別
      • 有毛細胞白血病(HCL)の罹患数:年齢別
    • 英国
      • 有毛細胞白血病(HCL)の罹患数
      • 有毛細胞白血病(HCL)の罹患数:症状別
      • 有毛細胞白血病(HCL)の罹患数:性別
      • 有毛細胞白血病(HCL)の罹患数:年齢別
  • 日本

第7章 有毛細胞白血病(HCL)の治療と管理

  • ESMO(欧州医療腫瘍学会)治療のための臨床診療ガイドライン
  • HCL-C患者の管理におけるコンセンサスガイドライン
  • NCCN臨床診療ガイドラインガイドライン
    • 治療法の選択肢
    • 治療ガイドライン

第8章 アンメットニーズ

第9章 上市済み治療薬

  • Lumoxiti:AstraZeneca
    • 医薬品概要
    • 規制のマイルストーン
    • その他の開発活動
    • 安全性と有効性
    • 製品プロファイル
  • Leustatin: Janssen
  • Nipent:Pfizer
  • Intron A:Merck
  • Roferon A:Roche
  • 適応外使用医薬品
  • リツキシマブ:Roche

第10章 新薬

  • キークロスコンペティション
  • Ibrutinib:Johnson and Johnson/Pharmacyclics
    • 医薬品概要
    • 規制のマイルストーン
    • その他の開発活動
    • 安全性と有効性
    • 製品プロファイル
  • Vemurafenib:Roche

第11章 有毛細胞白血病:主要7カ国市場の分析

  • 主な調査結果
  • 市場規模
    • 市場規模:治療薬別

第12章 市場の見通し:国別

第13章 米国:市場の見通し

  • 米国の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第14章 欧州5カ国:市場の見通し

  • ドイツの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • フランス
    • 総市場規模
    • 市場規模:治療薬別
  • イタリア
    • 総市場規模
    • 市場規模:治療薬別
  • スペイン
    • 総市場規模
    • 市場規模:治療薬別
  • 英国
    • 総市場規模
    • 市場規模:治療薬別

第15章 日本:市場の見通し

  • 総市場規模
  • 市場規模:治療薬別

第16章 市場の成長要因

第17章 市場の障壁

第18章 付録

  • 調査手法

第19章 DelveInsightのサービス内容

第20章 免責事項

第21章 DelveInsightについて

図表

List of Tables

  • Table 1 : 7MM Hairy Cell Leukemia (HCL) Epidemiology (2017-2030)
  • Table 2 : 7MM Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Hairy Cell Leukemia (HCL) Epidemiology in Germany (2017-2030)
  • Table 6 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Hairy Cell Leukemia (HCL) Epidemiology in France (2017-2030)
  • Table 8 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Hairy Cell Leukemia (HCL) Epidemiology in Italy (2017-2030)
  • Table 10 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Hairy Cell Leukemia (HCL) Epidemiology in Spain (2017-2030)
  • Table 12 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Hairy Cell Leukemia (HCL) Epidemiology in the UK (2017-2030)
  • Table 14 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Hairy Cell Leukemia (HCL) Epidemiology in Japan (2017-2030)
  • Table 16 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Hairy Cell Leukemia (HCL) Epidemiology (2017-2030)
  • Figure 2 : 7MM Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Hairy Cell Leukemia (HCL) Epidemiology in the United States (2017-2030)
  • Figure 4 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Hairy Cell Leukemia (HCL) Epidemiology in Germany (2017-2030)
  • Figure 6 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Hairy Cell Leukemia (HCL) Epidemiology in France (2017-2030)
  • Figure 8 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Hairy Cell Leukemia (HCL) Epidemiology in Italy (2017-2030)
  • Figure 10 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Hairy Cell Leukemia (HCL) Epidemiology in Spain (2017-2030)
  • Figure 12 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Hairy Cell Leukemia (HCL) Epidemiology in the UK (2017-2030)
  • Figure 14 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Hairy Cell Leukemia (HCL) Epidemiology in Japan (2017-2030)
  • Figure 16 : Hairy Cell Leukemia (HCL) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)
目次
Product Code: DIMI0089

DelveInsight's "Hairy Cell Leukemia (HCL) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hairy Cell Leukemia (HCL), historical and forecasted epidemiology as well as the Hairy Cell Leukemia (HCL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hairy Cell Leukemia (HCL) market report provides current treatment practices, emerging drugs, Hairy Cell Leukemia (HCL) market share of the individual therapies, current and forecasted Hairy Cell Leukemia (HCL) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hairy Cell Leukemia (HCL) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Hairy Cell Leukemia (HCL) Disease Understanding and Treatment Algorithm

The DelveInsight Hairy Cell Leukemia (HCL) market report gives a thorough understanding of the Hairy Cell Leukemia (HCL) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Hairy Cell Leukemia (HCL).

Treatment

It covers the details of conventional and current medical therapies available in the Hairy Cell Leukemia (HCL) market for the treatment of the condition. It also provides Hairy Cell Leukemia (HCL) treatment algorithms and guidelines in the United States, Europe, and Japan.

Hairy Cell Leukemia (HCL) Epidemiology

The Hairy Cell Leukemia (HCL) epidemiology division provide insights about historical and current Hairy Cell Leukemia (HCL) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hairy Cell Leukemia (HCL) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hairy Cell Leukemia (HCL) Epidemiology

The epidemiology segment also provides the Hairy Cell Leukemia (HCL) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hairy Cell Leukemia (HCL) Drug Chapters

Drug chapter segment of the Hairy Cell Leukemia (HCL) report encloses the detailed analysis of Hairy Cell Leukemia (HCL) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hairy Cell Leukemia (HCL) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Hairy Cell Leukemia (HCL) treatment.

Hairy Cell Leukemia (HCL) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Hairy Cell Leukemia (HCL) treatment.

Hairy Cell Leukemia (HCL) Market Outlook

The Hairy Cell Leukemia (HCL) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Hairy Cell Leukemia (HCL) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Hairy Cell Leukemia (HCL) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Hairy Cell Leukemia (HCL) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Hairy Cell Leukemia (HCL) market in 7MM.

The United States Market Outlook

This section provides the total Hairy Cell Leukemia (HCL) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Hairy Cell Leukemia (HCL) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Hairy Cell Leukemia (HCL) market size and market size by therapies in Japan is also mentioned.

Hairy Cell Leukemia (HCL) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Hairy Cell Leukemia (HCL) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Hairy Cell Leukemia (HCL) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hairy Cell Leukemia (HCL) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hairy Cell Leukemia (HCL) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Hairy Cell Leukemia (HCL) emerging therapies.

Reimbursement Scenario in Hairy Cell Leukemia (HCL)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Hairy Cell Leukemia (HCL) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hairy Cell Leukemia (HCL) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Hairy Cell Leukemia (HCL) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Hairy Cell Leukemia (HCL), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Hairy Cell Leukemia (HCL) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hairy Cell Leukemia (HCL) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hairy Cell Leukemia (HCL) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hairy Cell Leukemia (HCL) market

Report Highlights

  • In the coming years, Hairy Cell Leukemia (HCL) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hairy Cell Leukemia (HCL) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Hairy Cell Leukemia (HCL). Launch of emerging therapies will significantly impact the Hairy Cell Leukemia (HCL) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hairy Cell Leukemia (HCL)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hairy Cell Leukemia (HCL) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Hairy Cell Leukemia (HCL) Pipeline Analysis
  • Hairy Cell Leukemia (HCL) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hairy Cell Leukemia (HCL) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Hairy Cell Leukemia (HCL) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Hairy Cell Leukemia (HCL) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Hairy Cell Leukemia (HCL) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Hairy Cell Leukemia (HCL) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Hairy Cell Leukemia (HCL) market size during the forecast period (2017-2030)?
  • At what CAGR, the Hairy Cell Leukemia (HCL) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Hairy Cell Leukemia (HCL) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Hairy Cell Leukemia (HCL) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Hairy Cell Leukemia (HCL)?
  • What is the historical Hairy Cell Leukemia (HCL) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Hairy Cell Leukemia (HCL) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hairy Cell Leukemia (HCL)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Hairy Cell Leukemia (HCL) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Hairy Cell Leukemia (HCL) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Hairy Cell Leukemia (HCL) in the USA, Europe, and Japan?
  • What are the Hairy Cell Leukemia (HCL) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Hairy Cell Leukemia (HCL)?
  • How many therapies are developed by each company for Hairy Cell Leukemia (HCL) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Hairy Cell Leukemia (HCL) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Hairy Cell Leukemia (HCL) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hairy Cell Leukemia (HCL) and their status?
  • What are the key designations that have been granted for the emerging therapies for Hairy Cell Leukemia (HCL)?
  • What are the global historical and forecasted market of Hairy Cell Leukemia (HCL)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Hairy Cell Leukemia (HCL) market
  • To understand the future market competition in the Hairy Cell Leukemia (HCL) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hairy Cell Leukemia (HCL) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hairy Cell Leukemia (HCL) market
  • To understand the future market competition in the Hairy Cell Leukemia (HCL) market

Table of Contents

1. Key Insights

2. Executive Summary of Hairy Cell Leukemia (HCL)

3. Competitive Intelligence Analysis for Hairy Cell Leukemia (HCL)

4. Hairy Cell Leukemia (HCL): Market Overview at a Glance

  • 4.1. Hairy Cell Leukemia (HCL) Total Market Share (%) Distribution in 2017
  • 4.2. Hairy Cell Leukemia (HCL) Total Market Share (%) Distribution in 2030

5. Hairy Cell Leukemia (HCL): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Hairy Cell Leukemia (HCL) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Hairy Cell Leukemia (HCL) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Hairy Cell Leukemia (HCL) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Hairy Cell Leukemia (HCL) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Hairy Cell Leukemia (HCL) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Hairy Cell Leukemia (HCL) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Hairy Cell Leukemia (HCL) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Hairy Cell Leukemia (HCL) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Hairy Cell Leukemia (HCL) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Hairy Cell Leukemia (HCL) Treatment and Management
  • 8.2. Hairy Cell Leukemia (HCL) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Hairy Cell Leukemia (HCL) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Hairy Cell Leukemia (HCL): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Hairy Cell Leukemia (HCL) Market Size in 7MM
  • 13.3. Hairy Cell Leukemia (HCL) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Hairy Cell Leukemia (HCL) Total Market Size in the United States
    • 15.1.2. Hairy Cell Leukemia (HCL) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Hairy Cell Leukemia (HCL) Total Market Size in Germany
    • 15.3.2. Hairy Cell Leukemia (HCL) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Hairy Cell Leukemia (HCL) Total Market Size in France
    • 15.4.2. Hairy Cell Leukemia (HCL) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Hairy Cell Leukemia (HCL) Total Market Size in Italy
    • 15.5.2. Hairy Cell Leukemia (HCL) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Hairy Cell Leukemia (HCL) Total Market Size in Spain
    • 15.6.2. Hairy Cell Leukemia (HCL) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Hairy Cell Leukemia (HCL) Total Market Size in the United Kingdom
    • 15.7.2. Hairy Cell Leukemia (HCL) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Hairy Cell Leukemia (HCL) Total Market Size in Japan
    • 15.8.3. Hairy Cell Leukemia (HCL) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Hairy Cell Leukemia (HCL)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight